- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07923240
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders (MIF)
We aim to elucidate the metabolic and neuroactive properties of sequential Mexidol therapy in patients with and without cerebrometabolic disorders using blood biomarkers, anthropometry and brain functional MRI (task- and rest).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Moscow
-
Moscow, Moscow, Russia, 125367
- Russian Center of Neurology and Neurosciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- cerebrovascular disease (I67.8) and/or cerebral atherosclerosis (I67.2)
- metabolic disorders (diabetes and/or BMI 27 or higher) for Group1
- no metabolic disorders - for Group 2
Exclusion Criteria:
- decompensated somatic pathology
- history of neoplasia
- acute stroke/myocardial infarction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Cerebrovascular disease without metabolic disorders
|
14 days of 10,0 ml of Mexidol intravenous, followed by 2 months of oral administration |
|
Experimental: Cerebrovascular disease with metabolic disorders (obesity and/or DM2)
|
14 days of 10,0 ml of Mexidol intravenous, followed by 2 months of oral administration |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
fMRI
Time Frame: Days 1,2,14,74
|
Functional brain imaging changes (rest and task-based) - pre- and post-saline vs pre- and post-Mexidol |
Days 1,2,14,74
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BMI
Time Frame: 74 days
|
Body mass index canhge |
74 days
|
|
Cognitive
Time Frame: 74 days
|
Cognitive dynamics via MOCA test (maximum - 30, more = better) |
74 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Nutrition Disorders
- Overnutrition
- Body Weight
- Arteriosclerosis
- Arterial Occlusive Diseases
- Intracranial Arterial Diseases
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Overweight
- Obesity
- Cerebrovascular Disorders
- Intracranial Arteriosclerosis
Other Study ID Numbers
- 1-7/26
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.